Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review)
Photochemistry and Photobiology · 2024
DOI: 10.1111/php.13914 ↗At a glance
Übersichtsarbeit in Photochemistry and Photobiology, 2024. Written by Sanjay Anand and 2 co-authors. Institution: Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: Photochemotherapy, Photosensitizing Agents, Skin Neoplasms. Cited 15 times so far (Crossref); 129 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Photodynamic therapy (PDT) is a nonscarring cancer treatment in which a pro‐drug (5‐ aminolevulinic acid , ALA) is applied, converted into a photosensitizer (protoporphyrin IX, PpIX) which is then activated by visible light. ALA‐PDT is now popular for treating nonmelanoma skin cancer (NMSC), but can be ineffective for larger skin tumors, mainly due to inadequate production of PpIX. Work over the past two decades has shown that differentiation‐promoting agents, including methotrexate (MTX), 5‐fluorouracil (5FU) and vitamin D (Vit D) can be combined with ALA‐PDT as neoadjuvants to promote tumor‐specific accumulation of PpIX, enhance tumor‐selective cell death, and improve therapeutic outcome. In this review, we provide a historical perspective of how the combinations of differentiation‐promoting agents with PDT (cPDT) evolved, including Initial discoveries, biochemical and molecular mechanisms, and clinical translation for the treatment of NMSCs. For added context, we also compare the differentiation‐promoting neoadjuvants with some other clinical PDT combinations such as surgery, laser ablation, iron‐chelating agents (CP94), and immunomodulators that do not induce differentiation. Although this review focuses mainly on the application of cPDT for NMSCs, the concepts and findings described here may be more broadly applicable towards improving the therapeutic outcomes of PDT treatment for other types of cancers.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Dermatology and Plastic Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID profiles: Sanjay Anand, Edward V Maytin
Funding
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Anand, S., Hasan, T., & Maytin, E. V. (2024). Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review). Photochemistry and Photobiology. https://doi.org/10.1111/php.13914
Vancouver
Anand S, Hasan T, Maytin EV. Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review). Photochemistry and Photobiology. 2024. doi:10.1111/php.13914
BibTeX
@article{Anand2024,
author = {Anand, Sanjay and Hasan, Tayyaba and Maytin, Edward V},
title = {Treatment of nonmelanoma skin cancer with pro‐differentiation agents and photodynamic therapy: Preclinical and clinical studies (Review)},
journal = {Photochemistry and Photobiology},
year = {2024},
doi = {10.1111/php.13914}
}
EUVIMED